. Author manuscript; available in PMC: 2016 Feb 9.

Published in final edited form as: J Clin Lipidol. 2014 Oct 13;9(1):93–102. doi: 10.1016/j.jacl.2014.09.013

Table 1.

Baseline demographic characteristics

Parameter	Placebo (N = 41)	Anacetrapib alone (N = 95)	Atorvastatin alone (N = 44)	Anacetrapib + atorvastatin (N = 102)
Age, mean (SD)	53 (8)	58 (9)	56 (9)	56 (11)
Male gender, %	44	47	39	40
Race, % white	78	90	80	85
BMI, mean (SD)	32 (7)	30 (6)	29 (5)	31 (7)
% ≤TG median	56	57	39	51

BMI, body mass index; SD, standard deviation, TG, triglycerides.

Anacetrapib, combined anacetrapib 150- and 300-mg treatment groups; atorvastatin, atorvastatin 20 mg.